RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
ID: 355707Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355707

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) initiative, which aims to explore the role of RNA modifications in cancer development through a cooperative agreement mechanism. This funding opportunity seeks to support collaborative research projects that investigate how modifications in mRNA, tRNA, and rRNA influence translational reprogramming and contribute to oncogenesis, with a focus on the interactions between different RNA modifications during translation. A total of up to five U01 grants will be awarded, with a combined funding of $4.9 million for fiscal year 2025, and applications are due by November 4, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-029-Full-Announcement.html
    RFA-CA-24-029.html
    The National Cancer Institute (NCI) is inviting applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) initiative, focusing on the role of RNA modifications in cancer development. This funding opportunity, under the U01 Cooperative Agreement mechanism, aims to support fundamental studies on how modifications in mRNA, tRNA, and rRNA influence translational reprogramming involved in oncogenesis. Up to five U01 grants will be awarded, with a total funding of $4.9 million for FY 2025. Applications should explore the interplay of RNA modifications and their roles in cancer progression and therapy resistance. Investigators are encouraged to form collaborative teams comprising multiple principal investigators, covering diverse expertise in RNA biology and cancer research. The application deadline is November 5, 2024. Adherence to strict guidelines and collaboration among awardees are expected to promote innovation and knowledge sharing within this emerging research area.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative, aimed at advancing mechanistic research on RNA modifications that contribute to cancer development. This initiative seeks collaborative research projects that explore the role of mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation and progression, emphasizing the need for interdisciplinary expertise to address the complex interactions of these modifications. The estimated total program funding is $4.9 million, with an award ceiling of $650,000 for up to five projects, and the NOFO is expected to be published in early Fall 2024, with applications due in November 2024. Interested applicants are encouraged to prepare collaborations and can find additional information through the NCI Board of Scientific Advisors presentation linked in the opportunity overview.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)." This initiative invites revision applications from currently funded NCI R01 research projects, encouraging applicants to enhance their original research by integrating innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to foster interdisciplinary collaboration and accelerate scientific discovery in cancer research. Interested applicants can apply for grants of up to $150,000 annually for a maximum of two years, with applications accepted starting March 1, 2024, and a submission deadline of October 1, 2024. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html.
    Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Modular R01s in Cancer Control and Population Sciences grant, aimed at advancing research in cancer-related fields. This funding opportunity encourages innovative studies in areas such as epidemiology, cancer survivorship, healthcare delivery, and digital health, with the goal of addressing critical barriers in cancer research and promoting diversity among research topics. Eligible applicants include a wide range of organizations, including historically black colleges, tribal governments, and community-based organizations, with funding available up to $250,000 per year for a maximum of five years. Interested parties should submit their applications by November 5, 2024, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management" (RFA-CA-24-018). This initiative aims to support cooperative agreements that focus on the enhancement of emerging informatics technologies to improve data acquisition, management, analysis, and dissemination across the cancer research continuum. The program is particularly significant as it seeks to advance technologies that have shown initial viability but require further development to achieve a broader impact in cancer research, addressing critical health disparities and improving patient outcomes. NIH anticipates funding approximately four awards totaling $3.6 million for fiscal year 2025, with individual budgets capped at $600,000 per year over a five-year period. Applications are due by November 15, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at incorporating novel technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program to accelerate cancer research. This initiative encourages currently funded NCI P50 specialized centers to expand upon their original research questions by integrating innovative tools and methods, thereby promoting interdisciplinary collaboration and enhancing the rigor of ongoing studies. With a funding ceiling of $150,000 per year and a total of approximately $600,000 anticipated to support three awards for fiscal year 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Interested parties should submit their applications by October 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.